Sphere Bio will be attending NextGen Biomed, the premier meeting point for biologics drug discovery and development. This event unites six major industry communities on one platform, enabling over 30,000 biologics and therapeutic R&D professionals to collaborate, align expertise, and drive innovation. With a focus on accelerating life-saving treatments sustainably and at scale, NextGen Biomed offers an unparalleled opportunity to build partnerships, exchange knowledge, and transform novel therapies into impactful patient outcomes.
Join us to explore advancements shaping the future of biopharma.
Presentation Talk
Day 1
Maryam Ahmadi, Director of Science
Presentation Abstract
Sphere Bio’s Cyto-Mine® Chroma advances antibody discovery and cell line development with microfluidics & multi-laser single-cell analysis. It enables high-throughput screening, accurately sorting cells by productivity & viability, accelerating therapeutic development.
Richard Hammond, CTO
Panel Session
Day 2
Panelists:
- BERIT OLSEN KROGH, Senior Research Fellow, Lundbeck
- ANDREW BUCHANAN, Principal Scientist, Biologics Engineering, AstraZeneca
- RICHARD HAMMOND, Chief Technical Officer, Sphere Bio
